ALTO NEUROSCIENCE INC (ANRO) Stock Overview
USA - NYSE:ANRO - US02157Q1094 - Common Stock
ANRO Key Statistics, Chart & Performance
The current stock price of ANRO is 6.08 USD. In the past month the price increased by 68.89%. In the past year, price decreased by -57.87%.
ANRO Latest News, Press Relases and Analysis
ANRO Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 49.71 | 759.85B | ||
| JNJ | JOHNSON & JOHNSON | 18.61 | 465.34B | ||
| AZN | ASTRAZENECA PLC-SPONS ADR | 19.07 | 262.58B | ||
| NVS | NOVARTIS AG-SPONSORED ADR | 14.85 | 254.43B | ||
| NVO | NOVO-NORDISK A/S-SPONS ADR | 13.94 | 241.59B | ||
| MRK | MERCK & CO. INC. | 11.01 | 211.79B | ||
| PFE | PFIZER INC | 7.23 | 139.35B | ||
| SNY | SANOFI-ADR | 11.4 | 123.36B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 6.48 | 88.81B | ||
| GSK | GSK PLC-SPON ADR | 9.74 | 88.32B | ||
| ZTS | ZOETIS INC | 23.16 | 63.84B | ||
| TAK | TAKEDA PHARMACEUTIC-SP ADR | 48.41 | 44.34B |
Related stock screener links
About ANRO
Company Profile
Alto Neuroscience, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of psychiatric drugs. The company is headquartered in Mountain View, California and currently employs 76 full-time employees. The company went IPO on 2024-02-02. The firm's Precision Psychiatry Platform measures brain biomarkers by analyzing EEG activity, neurocognitive assessments, wearable data, and other factors to identify which patients are likely to respond to its product candidates. Its clinical-stage pipeline includes drug candidates in bipolar depression, major depressive disorder, treatment resistant depression (TRD), and schizophrenia, and other mental health conditions. Its product candidates include ALTO-100, ALTO-300, ALTO-207, ALTO-203, ALTO-101, ALTO-202, and ALTO-208. ALTO-100 is a first-in-class, oral small molecule believed to work through enhancing neural plasticity in the hippocampus, a brain region important for both cognition and mood. ALTO-203 is an oral small molecule histamine H3 receptor inverse agonist.
Company Info
ALTO NEUROSCIENCE INC
650 Castro Street, Suite 450
Mountain View CALIFORNIA US
Employees: 76
Phone: 17732555012
ALTO NEUROSCIENCE INC / ANRO FAQ
What is the stock price of ALTO NEUROSCIENCE INC today?
The current stock price of ANRO is 6.08 USD. The price increased by 3.4% in the last trading session.
What is the ticker symbol for ALTO NEUROSCIENCE INC stock?
The exchange symbol of ALTO NEUROSCIENCE INC is ANRO and it is listed on the New York Stock Exchange, Inc. exchange.
On which exchange is ANRO stock listed?
ANRO stock is listed on the New York Stock Exchange, Inc. exchange.
What is the price forecast or stock price prediction for ALTO NEUROSCIENCE INC stock?
15 analysts have analysed ANRO and the average price target is 10.54 USD. This implies a price increase of 73.36% is expected in the next year compared to the current price of 6.08. Check the ALTO NEUROSCIENCE INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is ALTO NEUROSCIENCE INC worth?
ALTO NEUROSCIENCE INC (ANRO) has a market capitalization of 164.65M USD. This makes ANRO a Micro Cap stock.
How many employees does ALTO NEUROSCIENCE INC have?
ALTO NEUROSCIENCE INC (ANRO) currently has 76 employees.
What are the support and resistance levels for ALTO NEUROSCIENCE INC (ANRO) stock?
ALTO NEUROSCIENCE INC (ANRO) has a support level at 5.99 and a resistance level at 6.9. Check the full technical report for a detailed analysis of ANRO support and resistance levels.
Should I buy ALTO NEUROSCIENCE INC (ANRO) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of ANRO, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of ANRO, evaluating the profitability, health, valuation and growth aspects
- ALTO NEUROSCIENCE INC (ANRO) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- ALTO NEUROSCIENCE INC (ANRO) Sales and EPS estimates to see what analysts future expectations are.
- ALTO NEUROSCIENCE INC (ANRO) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- ALTO NEUROSCIENCE INC (ANRO) Insider and Institutional Ownership to learn about the owners and their transactions.
- ALTO NEUROSCIENCE INC (ANRO) Stock Chart to make your own analysis
- ALTO NEUROSCIENCE INC (ANRO) Latest news and press-releases to stay up to date.
Does ALTO NEUROSCIENCE INC (ANRO) stock pay dividends?
ANRO does not pay a dividend.
When does ALTO NEUROSCIENCE INC (ANRO) report earnings?
ALTO NEUROSCIENCE INC (ANRO) will report earnings on 2025-11-12, after the market close.
What is the Price/Earnings (PE) ratio of ALTO NEUROSCIENCE INC (ANRO)?
ALTO NEUROSCIENCE INC (ANRO) does not have a PE ratio as the earnings reported over the last twelve months were negative (-2.39).
What is the Short Interest ratio of ALTO NEUROSCIENCE INC (ANRO) stock?
The outstanding short interest for ALTO NEUROSCIENCE INC (ANRO) is 6.62% of its float. Check the ownership tab for more information on the ANRO short interest.
ANRO Technical Analysis
ChartMill assigns a technical rating of 9 / 10 to ANRO. When comparing the yearly performance of all stocks, ANRO is one of the better performing stocks in the market, outperforming 87.6% of all stocks.
ANRO Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to ANRO. The financial health of ANRO is average, but there are quite some concerns on its profitability.
ANRO Financial Highlights
Over the last trailing twelve months ANRO reported a non-GAAP Earnings per Share(EPS) of -2.39. The EPS increased by 13.41% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -41.08% | ||
| ROE | -52.55% | ||
| Debt/Equity | 0.18 |
ANRO Forecast & Estimates
15 analysts have analysed ANRO and the average price target is 10.54 USD. This implies a price increase of 73.36% is expected in the next year compared to the current price of 6.08.